Drug combo shrinks melanoma tumors before surgery, may prevent return
NCT ID NCT02231775
First seen Feb 16, 2026 · Last updated May 12, 2026 · Updated 10 times
Summary
This study tested whether giving two targeted drugs (dabrafenib and trametinib) before and after surgery helps people with stage III melanoma that has a BRAF gene mutation. The drugs block signals that help cancer grow, shrinking tumors before surgery and killing leftover cells afterward. The trial enrolled 58 adults with stage IIIB or IIIC melanoma to see if this approach improves how long people stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB CUTANEOUS MELANOMA AJCC V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.